Judge Asked To Skillax To Attend ‘Stairway’
Written by ABR on 18/05/2016
“Consider heart disease, the No. 1 killer of women, killing more women than all cancers combined. If we can do more to prevent, treat and cure cardiovascular disease, more women will live longer, more families will stay together, more workers will stay productive, and we’ll save money on treating a condition that costs the U.S. nearly a billion dollars a day.
“Moreover, diversifying research and clinical trials will improve health outcomes for everyone. Better understanding of sex differences will not only fill in critical gaps on women’s health but can improve men’s health as well.
“To give an example, looking at disease through the sex and gender lens has driven new insights regarding atrial fibrillation (AFib), a dangerous condition marked by an irregular heartbeat that can lead to stroke, blood clots, heart failure and other heart complications. For many years, research failed to find an association between physical activity and AFib. Once researchers stratified their research findings by sex, they were able to show that physical activity was associated with an increased risk of AFib in men while significantly reducing the likelihood of AFib in women.
Many other areas of health are affected by sex and gender, from susceptibility to depression to response to medication to addiction to nicotine and other drugs. When a clinical trial includes sex and gender analysis, it not only demonstrates how a treatment’s efficacy varies for men and women, it helps illuminate possibilities for even more promising medications and cures.
“Last month, the U.S. Senate HELP Committee passed a series of biomedical innovation bills, which can be bundled into a companion to the House-passed 21st Century Cures Act. We applaud this bipartisan commitment to fighting disease and saving lives. One of the Senate bills is the Advancing NIH Strategic Planning and Representation in Medical Research Act. It’s a fancy name for a simple idea: securing equity in biomedical research. Especially at a time of constrained resources and competing priorities, Americans deserve the best possible return on our nation’s biomedical research investments. We urge the Congress to pass this legislation, for our health and for our future.”